Stock listing
ASX:RAD Radiopharm Theranostics Limited Share Price
Home listing (ASX) of Radiopharm Theranostics Limited
Follow Radiopharm Theranostics Limited into a list and get an email when it puts out news.
Share price · ASX:RAD
$0.0040 AUD +0.0010 (+33.3%)
Close on Nov 20, 2026
- Day range
- $0.0030 – $0.0040 AUDNov 20, 2026
- Volume
- 1.67M sharesNov 20, 2026
- Market cap
- $17.51M AUDAt the close on Nov 20, 2026 · price × 4.38B shares outstanding
- 52-week range
- $0.0030 – $0.0370 AUDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $54,387 AUDMedian day 3.55M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| ASX:RAD · Home | $0.0040 AUD | +0.0010 (+33.3%) | 1,666,666 | $0.0030 | $0.0040 | $0.0030 | $0.0030 | Close on Nov 20, 2026 |
| NASDAQ:RADX | $0.63 USD | -0.043 (-6.3%) | 12,982 | $0.716 | $0.716 | $0.63 | $0.673 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · ASX:RAD · AUD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.0040 | +0.0010 | +33.3% | $0.0030 | $0.0040 | $0.0030 | 1,666,666 | |
| $0.0030 | 0.0000 | 0.0% | $0.0040 | $0.0040 | $0.0030 | 11,419,577 | |
| $0.0030 | 0.0000 | 0.0% | $0.0030 | $0.0030 | $0.0030 | 1,816,011 | |
| $0.0030 | -0.0010 | -25.0% | $0.0030 | $0.0030 | $0.0030 | 21,752,520 | |
| $0.0040 | 0.0000 | 0.0% | $0.0040 | $0.0040 | $0.0030 | 1,248,716 | |
| $0.0040 | 0.0000 | 0.0% | $0.0040 | $0.0040 | $0.0035 | 468,690 | |
| $0.0040 | 0.0000 | 0.0% | $0.0040 | $0.0040 | $0.0040 | 623,785 | |
| $0.0040 | 0.0000 | 0.0% | $0.0040 | $0.0040 | $0.0030 | 20,184,407 | |
| $0.0040 | 0.0000 | 0.0% | $0.0040 | $0.0040 | $0.0035 | 3,796,694 | |
| $0.0040 | 0.0000 | 0.0% | $0.0030 | $0.0040 | $0.0030 | 26,084,275 | |
| $0.0040 | +0.0010 | +33.3% | $0.0030 | $0.0040 | $0.0030 | 3,493,295 | |
| $0.0030 | -0.0010 | -25.0% | $0.0040 | $0.0040 | $0.0030 | 6,115,697 | |
| $0.0040 | +0.0010 | +33.3% | $0.0030 | $0.0040 | $0.0030 | 11,288,609 | |
| $0.0030 | -0.0020 | -40.0% | $0.0040 | $0.0040 | $0.0030 | 24,480,673 | |
| $0.0050 | 0.0000 | 0.0% | $0.0050 | $0.0050 | $0.0040 | 10,433,448 | |
| $0.0050 | +0.0010 | +25.0% | $0.0040 | $0.0050 | $0.0040 | 66,268 | |
| $0.0040 | -0.0005 | -11.1% | $0.0040 | $0.0045 | $0.0040 | 74,363 | |
| $0.0045 | +0.0005 | +12.5% | $0.0040 | $0.0045 | $0.0040 | 123,285 | |
| $0.0040 | -0.0010 | -20.0% | $0.0040 | $0.0045 | $0.0035 | 12,107,871 | |
| $0.0050 | +0.0005 | +11.1% | $0.0040 | $0.0050 | $0.0040 | 2,918,823 | |
| $0.0045 | +0.0005 | +12.5% | $0.0040 | $0.0045 | $0.0040 | 541,452 | |
| $0.0040 | -0.0005 | -11.1% | $0.0040 | $0.0040 | $0.0040 | 6,779,489 | |
| $0.0045 | +0.0005 | +12.5% | $0.0040 | $0.0045 | $0.0040 | 3,017,597 | |
| $0.0040 | -0.0010 | -20.0% | $0.0050 | $0.0050 | $0.0040 | 1,926,768 | |
| $0.0050 | +0.0010 | +25.0% | $0.0040 | $0.0050 | $0.0040 | 2,214,524 | |
| $0.0040 | -0.0010 | -20.0% | $0.0050 | $0.0050 | $0.0035 | 19,882,025 | |
| $0.0050 | 0.0000 | 0.0% | $0.0050 | $0.0050 | $0.0040 | 3,554,924 | |
| $0.0050 | 0.0000 | 0.0% | $0.0050 | $0.0050 | $0.0040 | 2,645,028 | |
| $0.0050 | 0.0000 | 0.0% | $0.0050 | $0.0050 | $0.0040 | 915,886 | |
| $0.0050 | 0.0000 | 0.0% | $0.0050 | $0.0055 | $0.0045 | 2,391,794 | |
| $0.0050 | 0.0000 | 0.0% | $0.0050 | $0.0050 | $0.0045 | 4,212,449 | |
| $0.0050 | -0.0005 | -9.1% | $0.0050 | $0.0055 | $0.0050 | 1,781,690 | |
| $0.0055 | +0.0005 | +10.0% | $0.0050 | $0.0055 | $0.0050 | 2,147,327 | |
| $0.0050 | -0.0010 | -16.7% | $0.0060 | $0.0060 | $0.0050 | 11,577,310 | |
| $0.0060 | -0.0010 | -14.3% | $0.0060 | $0.0060 | $0.0055 | 25,194,511 | |
| $0.0070 | +0.0010 | +16.7% | $0.0065 | $0.0070 | $0.0060 | 10,717,667 | |
| $0.0060 | 0.0000 | 0.0% | $0.0070 | $0.0070 | $0.0060 | 29,059,985 | |
| $0.0060 | -0.0010 | -14.3% | $0.0070 | $0.0070 | $0.0060 | 1,284,520 | |
| $0.0070 | 0.0000 | 0.0% | $0.0070 | $0.0080 | $0.0070 | 10,065,449 | |
| $0.0070 | -0.0010 | -12.5% | $0.0070 | $0.0075 | $0.0070 | 2,738,943 | |
| $0.0080 | +0.0010 | +14.3% | $0.0070 | $0.0080 | $0.0070 | 2,633,422 | |
| $0.0070 | 0.0000 | 0.0% | $0.0070 | $0.0075 | $0.0070 | 2,507,645 | |
| $0.0070 | -0.0010 | -12.5% | $0.0080 | $0.0080 | $0.0065 | 8,344,482 | |
| $0.0080 | +0.0010 | +14.3% | $0.0080 | $0.0080 | $0.0070 | 4,006,670 | |
| $0.0070 | -0.0010 | -12.5% | $0.0080 | $0.0080 | $0.0065 | 12,467,000 | |
| $0.0080 | +0.0010 | +14.3% | $0.0070 | $0.0080 | $0.0070 | 2,965,576 | |
| $0.0070 | -0.0010 | -12.5% | $0.0075 | $0.0080 | $0.0070 | 3,903,163 | |
| $0.0080 | 0.0000 | 0.0% | $0.0080 | $0.0080 | $0.0070 | 3,982,978 | |
| $0.0080 | -0.0010 | -11.1% | $0.0090 | $0.0090 | $0.0070 | 60,154,171 | |
| $0.0090 | +0.0010 | +12.5% | $0.0080 | $0.0090 | $0.0080 | 4,216,769 | |
| $0.0080 | -0.0010 | -11.1% | $0.0090 | $0.0090 | $0.0080 | 20,015,355 | |
| $0.0090 | 0.0000 | 0.0% | $0.0090 | $0.0095 | $0.0090 | 7,630,853 | |
| $0.0090 | 0.0000 | 0.0% | $0.0090 | $0.0100 | $0.0090 | 2,986,595 | |
| $0.0090 | -0.0010 | -10.0% | $0.0100 | $0.0100 | $0.0090 | 1,814,096 | |
| $0.0100 | +0.0010 | +11.1% | $0.0090 | $0.0100 | $0.0090 | 503,545 | |
| $0.0090 | -0.0010 | -10.0% | $0.0090 | $0.0100 | $0.0090 | 6,132,273 | |
| $0.0100 | +0.0010 | +11.1% | $0.0090 | $0.0100 | $0.0090 | 2,909,828 | |
| $0.0090 | -0.0010 | -10.0% | $0.0100 | $0.0100 | $0.0090 | 3,436,988 | |
| $0.0100 | 0.0000 | 0.0% | $0.0100 | $0.0100 | $0.0095 | 525,334 | |
| $0.0100 | +0.0010 | +11.1% | $0.0100 | $0.0100 | $0.0090 | 5,637,590 | |
| $0.0090 | -0.0010 | -10.0% | $0.0100 | $0.0100 | $0.0090 | 414,931 | |
| $0.0100 | 0.0000 | 0.0% | $0.0110 | $0.0110 | $0.0090 | 4,855,069 | |
| $0.0100 | -0.0005 | -4.8% | $0.0110 | $0.0110 | $0.0100 | 7,137,112 | |
| $0.0105 | -0.0005 | -4.5% | $0.0110 | $0.0110 | $0.0105 | 617,704 | |
| $0.0110 | +0.0010 | +10.0% | $0.0100 | $0.0110 | $0.0100 | 3,306,588 | |
| $0.0100 | 0.0000 | 0.0% | $0.0100 | $0.0110 | $0.0100 | 4,959,375 | |
| $0.0100 | -0.0020 | -16.7% | $0.0120 | $0.0120 | $0.0090 | 78,037,359 |
- Ticker
- ASX:RAD
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- ASX
- Currency
- AUD
What changed lately
Latest news release · Nov 15, 2026
RAD interim analysis at SNO26 on RAD101 Phase IIb data
Latest deck · October 2026
Investor Presentation (October 2026)
Investor deck · 38 slides
Latest news
RAD interim analysis at SNO26 on RAD101 Phase IIb data
Nov 15, 2026
Closed $0.0040 (0.0%) on Nov 16, 2026
Change of Director's Interest Notices x 4
Nov 10, 2026
Closed $0.0040 (0.0%) on Nov 11, 2026
RAD Alignment with US FDA for Development of RAD101
Nov 3, 2026
Closed $0.0040 (+33.3%) on Nov 4, 2026
Quarterly Activities/Appendix 4C Cash Flow Report
Oct 30, 2026
Closed $0.0050 (0.0%) on Nov 2, 2026
Notice of Annual General Meeting/Proxy Form
Oct 26, 2026
Closed $0.0040 (-20.0%) on Oct 27, 2026
Radiopharm receives $8M advance on FY26 R&D tax incentive
Oct 26, 2026
Closed $0.0050 (+11.1%) on Oct 26, 2026
Notification regarding unquoted securities - RAD
Oct 20, 2026
Closed $0.0040 (-20.0%) on Oct 20, 2026
Notification of cessation of securities - RAD
Oct 20, 2026
Closed $0.0040 (-20.0%) on Oct 20, 2026
Non-Compliance with Listing Rule 10.11
Oct 11, 2026
Closed $0.0050 (0.0%) on Oct 12, 2026
Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101
Oct 5, 2026
Closed $0.0050 (-16.7%) on Oct 6, 2026
Radiopharm Theranostics Limited on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 76 in the last 12 months · 168 in all · newest Nov 15, 2026 · oldest 2021
- Decks
- 28 decks · latest October 2026
Where Radiopharm Theranostics Limited is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| ASX:RAD · Home listing · This page | ASX | Australia | AUD |
| NASDAQ:RADX | NASDAQ | United States | USD |
| OTC:RDPTF | OTC | United States | USD |
| BOATS:RADX | BOATS | United States | USD |
Valuation
EV/sales 4.8× against a median of 26.5×: 3rd lowest of 6 Biotechnology companies shown. Statements: Year to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- $13.37M AUD
- P/E
- Loss
- EV/sales
- 4.8×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.7×
- Gross margin
- −77.7%
- Operating margin
- Revenue too small
- Net margin
- Revenue too small
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Radiopharm Theranostics Limited · ASX:RAD | US$11.59M | US$8.85M | n/a | 4.8× | n/a | 0.7× | n/a | 0.0× | n/a |
| BioCardia, Inc. · NASDAQ:BCDA | US$11.88M | US$10.22M | n/a | n/a | n/a | 14.2× | n/a | 0.7× | 0.42 |
| Xintela AB · OMXSTO:XINT | US$11.88M | US$11.81M | n/a | 39.8× | n/a | n/a | n/a | n/a | n/a |
| Pluri Inc. · NASDAQ:PLUR | US$11.85M | US$38.65M | n/a | 26.5× | n/a | n/a | n/a | n/a | 0.53 |
| Synlogic Inc · OTC:SYBX | US$11.76M | US$201,442 | n/a | n/a | n/a | 1.2× | n/a | 0.0× | 0.50 |
| Imugene Ltd · ASX:IMU | US$11.74M | US$14.16M | n/a | n/a | n/a | 2.0× | n/a | 0.7× | n/a |
| Aelis Farma SA · EURONEXT:AELIS | US$11.55M | US$9.09M | n/a | 4.0× | n/a | 4.5× | −308.7% | 1.9× | n/a |
| Simris Group AB Class B · OMXSTO:SIMRIS_B | US$11.54M | US$19.53M | n/a | 144× | n/a | 154× | n/a | 117× | n/a |
| Dyadic International, Inc. · NASDAQ:DYAI | US$11.51M | US$12.03M | n/a | 3.9× | n/a | n/a | −226.9% | n/a | 1.12 |
| Psyence Biomedical Ltd. · NASDAQ:PBM | US$11.33M | US$4.18M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.90 |
| Medicenna Therapeutics Corp. · TSX:MDNA | US$11.26M | US$7.37M | n/a | n/a | n/a | 9.7× | n/a | 0.1× | 1.36 |
| Median of the others | US$11.64M | US$11.02M | 26.5× | 4.5× | −267.8% | 0.7× | 0.72 |
Forecasts
Analysts' consensus from EODHD, read Nov 17, 2026. Not 6ix's view and not investment advice.
- Price target
- 0.15 AUD · Analysts' mean
- EPS, year to Jun 2027
- -0.014 · 1 analyst
- Revenue, year to Jun 2027
- 1.06M · 5 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Riccardo Canevari | Managing Director and CEO |
| Barbara Lani | VP Quality Affairs |
| Donna Supko | VP Regulatory Affairs |
| Emily Love-Leon | VP Clinical Operations |
| Levente Meszaros | VP Preclinical and Translational Science |
| Melissa Thomas | VP Portfolio Program Lead |
| Sherin Al-Safadi | VP Medical and Corporate Affairs |
| Vimal Patel | VP CMC |
| Dimitris Voliotis | Chief Medical Officer |
| Hitesh Goel | Head of Project Management |
| Paul Hopper | Executive Chairman |
Board
| Director | Role |
|---|---|
| Paul Hopper | Executive Chairman |
| Hester Larkin | Non - Executive Director |
| Ian Turner | Non - Executive Director |
| Noel Donnelly | Non Executive Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Mar 31, 2026 | Jun 3, 2026 | −9.5% |
| Q2 2026 | Feb 26, 2026 | +4.5% |
| Quarter to Sep 30, 2025 | Dec 3, 2025 | −4.5% |
| Q4 2025 | Sep 16, 2025 | +9.7% |
| Quarter to Mar 31, 2025 | May 28, 2025 | −8.0% |
| Q2 2025 | Feb 28, 2025 · Before open | 0.0% |
| Q1 2025 | Nov 27, 2024 | +7.1% |
| Q4 2024 | Aug 29, 2024 | +12.1% |
| Q3 2024 | Apr 15, 2024 · Before open | −2.1% |
| Q2 2024 | Feb 29, 2024 · Before open | +16.1% |
All 17 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Nov 29, 2023 | +2.8% |
| Q4 2023 | Aug 30, 2023 · After close | 0.0% |
| Q3 2023 | May 31, 2023 | −3.6% |
| Q2 2023 | Feb 28, 2023 · Before open | −3.7% |
| Q1 2023 | Nov 30, 2022 | +4.5% |
| Q4 2022 | Aug 30, 2022 · After close | −8.6% |
| Q2 2022 | Feb 27, 2022 · After close | −2.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2026) | Investor deck | 38 slides | October 2026 |
| Investor Presentation (July 2026) | Investor deck | 31 slides | Jul 24, 2026 |
| Investor Presentation (June 2026) | Investor deck | 41 slides | June 2026 |
| Investor Presentation (December 2025) | Investor deck | 60 slides | December 2025 |
| Shareholder Meeting (November 2025) | Shareholder meeting | 22 slides | Nov 20, 2025 |
| Investor Presentation (November 2025) | Investor deck | 60 slides | Nov 1, 2025 |
| Investor Presentation (October 2025) | Investor deck | 54 slides | Oct 20, 2025 |
| Corporate Update (October 2025) | Corporate update | 43 slides | Oct 20, 2025 |
| Investor Presentation (August 2025) | Investor deck | 61 slides | August 2025 |
| Shareholder Meeting (November 2024) | Shareholder meeting | 12 slides | Nov 25, 2024 |
All 28 decks
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Share purchase plan of sPP Shares with SPP Attaching Options Closed: A$3M raised · A$0.009 a share · Warrants at A$0.018 Buyers: Trading Capital Management (HK) Ltd (~A$1.5 million pursuant to a shortfall commitment) Insiders: ~A$0.1 million subscribed by participating Directors Use of proceeds: RAD101 registrational study, advancing therapeutic programs, strategic partnering, working capital and general corporate purposes | Sep 17, 2026 | US$2.13M |
| Registered direct offering of american Depositary Shares with unregistered warrants Announced: about US$4.1M · US$3.16 a share · Warrants at US$3.79 · H.C. Wainwright & Co. Dealers: H.C. Wainwright & Co. (lead) Use of proceeds: RAD101 registrational study, advancing therapeutic programs, strategic partnering, working capital and general corporate purposes | Jul 27, 2026 | |
| Private placement of ordinary shares with attaching options Announced: about A$6.7M · Warrants at A$0.018 Use of proceeds: RAD101 registrational study, advancing therapeutic programs, strategic partnering, working capital and general corporate purposes | Jul 27, 2026 | US$4.68M |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in AUD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 2.77M | 3.63M | 299.2K | 292.4K | 8.83K | 0 |
| Cost of revenue | 4.92M | 3.59M | 2.98M | |||
| Gross profit | -2.15M | 39.3K | 299.2K | 292.4K | -2.97M | |
| Research and development | 50.0M | 27.5M | 23.1M | 22.6M | 7.49M | |
| Selling, general and administrative | 18.6M | 12.4M | 300.6K | |||
| Operating income | -68.3M | -38.2M | -47.2M | -34.5M | -19.9M | -484.8K |
| Depreciation and amortization | 7.33K | 2.60M | 3.13M | 3.30M | 2.98M | 1.16M |
| EBITDA | -68.3M | -35.6M | -44.1M | -31.2M | -16.9M | 678.7K |
| Interest expense | 112.4K | 65.3K | 642.9K | 86.1K | 9.35M | 0 |
| Income before tax | -56.9M | -38.2M | -47.9M | -34.6M | -30.3M | -485.2K |
| Income tax | -54.4K | 103.3K | 96.4K | 38.0K | 44.4K | -1.16M |
| Net income | -55.1M | -38.3M | -47.9M | -34.6M | -30.3M | -485.2K |
| Earnings per share, basic | -0.02 | -1.76 | -12.41 | -11.32 | -0.11 | -0.00 |
| Earnings per share, diluted | -1.76 | -12.41 | -11.32 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 4.14M | 29.1M | 18.6M | 11.7M | 27.0M | 27.1K |
| Receivables | 17.4M | 10.4M | 987.4K | 4.47M | 56.5K | 6.35K |
| Inventory | 1 | -6.35K | ||||
| Current assets | 21.9M | 39.9M | 22.8M | 27.3M | 33.4K | |
| Property, plant and equipment | 53.5K | 60.8K | 1.58K | |||
| Total assets | 60.1M | 86.5M | 72.0M | 83.4M | 33.4K | |
| Accounts payable | 5.47M | 9.34M | 10.9M | 5.12M | 1.19M | 64.4K |
| Current liabilities | 18.9M | 14.9M | 17.6M | 7.88M | 158.1K | |
| Total debt | 59.0K | |||||
| Total liabilities | 37.8M | 43.6M | 44.7M | 20.4M | 158.1K | |
| Shareholders' equity | 24.7M | 42.9M | 27.4M | 45.6M | 63.0M | -124.7K |
| Shares outstanding | 3.54B | 279.8M | 277.5M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Cash from operations | -52.8M | -36.6M | -23.0M | -23.2M | -9.91M | -32.9K |
| Capital spending | -52.8M | -45.3K | -28.3M | -1 | ||
| Free cash flow | -52.8M | -23.2M | -38.2M | -32.9K | ||
| Cash from investing | -5.42M | 1.77M | -320.0K | -1.53M | -28.4M | -28.4M |
| Cash from financing | 33.4M | 45.4M | 30.2M | 9.22M | 65.1M | 60.0K |
| Share buybacks | -4.83M | 1.00K | ||||
| Change in cash | -25.0M | 10.6M | 6.90M | -15.5M | 27.0M | 27.1K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 6-K · Report of a foreign issuer | Nov 16, 2026 | Current report | SEC |
| RAD interim analysis at SNO26 on RAD101 Phase IIb data | Nov 15, 2026 | Other filings | ASX |
| SCHEDULE 13G · Big-stake notice | Nov 13, 2026 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Nov 12, 2026 | Current report | SEC |
| Change of Director's Interest Notices x 4 | Nov 10, 2026 | Ownership change notice | ASX |
| 6-K · Report of a foreign issuer | Nov 4, 2026 | Current report | SEC |
| RAD Alignment with US FDA for Development of RAD101 | Nov 3, 2026 | Other filings | ASX |
| 6-K · Report of a foreign issuer | Oct 30, 2026 | Current report | SEC |
| Quarterly Activities/Appendix 4C Cash Flow Report | Oct 30, 2026 | Quarterly report | ASX |
| Quarterly Activities/Appendix 4C Cash Flow Report | Oct 30, 2026 | Quarterly report | ASX |
Show 200 filings
This page holds 200 of 290 filings. Open Filings
Cap table
Built by 6ix from Radiopharm Theranostics Limited’s releases · as of Sep 17, 2026
- Common shares
- 4,377,549,491
- Fully diluted
- 4,377,549,491
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 4,377,549,491 |
Warrants and options
| Lot |
|---|
| Warrants · A$0.018 · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 4,377,549,491 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Aaron Laurita Other companies: Immuron Limited (Chief Financial Officer · Since at least Feb 9, 2026) | Chief Financial Officer · Since at least Mar 18, 2026 |
| Noel Donnelly Other companies: PepGen Inc. (Chief Financial Officer · Since at least May 5, 2022) | Director · Since at least Mar 18, 2026 |
| Barbara Lani | VP Quality Affairs · Since at least Nov 5, 2026 |
| Bruce Michael Goodwin | Director · Since at least Mar 18, 2026 |
| Dimitris Voliotis | Chief Medical Officer · Since at least Aug 26, 2026 |
| Donna Supko | VP Regulatory Affairs · Since at least Nov 4, 2026 |
| Emily Love-Leon | VP Clinical Operations · Since at least Nov 4, 2026 |
| Hester Larkin | Non - Executive Director · Since at least Nov 5, 2026 |
| Hitesh Goel | Head of Project Management · Since at least Nov 5, 2026 |
| Ian Turner | Non - Executive Director · Since at least Mar 18, 2026 |
All 17 people
| Person | Seat |
|---|---|
| John M. Viglotti | SVP Corporate Services · Nov 5, 2025 – Nov 5, 2026 · Past |
| Levente Meszaros | VP Preclinical and Translational Science · Since at least Nov 5, 2026 |
| Melissa Thomas | VP Portfolio Program Lead · Since at least Nov 5, 2026 |
| Paul Hopper | Executive Chairman · Since at least Mar 18, 2026 |
| Riccardo Canevari | Managing Director and CEO · Since at least Oct 5, 2026 |
| Sherin Al-Safadi | VP Medical and Corporate Affairs · Since at least Nov 5, 2026 |
| Vimal Patel | VP CMC · Since at least Nov 5, 2026 |
Log in to ask 6ix AI your own questions about Radiopharm Theranostics Limited.